Finance

Beta
Lists
4XC1:FRA
Kalvista Pharmaceuticals Inc
€22.73
0.00%
(0.00) 1D
Jun 10, 8:05:23 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 4XC1...
Mkt. cap
1.44B
Avg. vol.
22.00
Volume
0.00
52-wk high
€23.26
52-wk low
€9.00
No. of employees
275
Mkt. cap
1.44B
Avg. vol.
22.00
Volume
0.00
52-wk high
€23.26
52-wk low
€9.00
No. of employees
275
News stories
From sources across the web
About Kalvista Pharmaceuticals Inc
CEO-
Employees275
Founded2004
HeadquartersFramingham, Massachusetts, United States
SectorBiotechnology
Websitekalvista.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Oct 2024
Sep 2025
Dec 2025
Mar 2026
Revenue
-
13.69M
59.92M
40.86M
Cost of goods sold
16.61M
13.22M
12.24M
15.51M
Cost of revenue
16.61M
13.22M
12.24M
15.51M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
29.20M
30.35M
60.40M
48.80M
Operating expense
29.20M
30.35M
60.40M
44.68M
Total operating expenses
45.81M
59.74M
72.64M
64.30M
Operating income
-45.81M
-46.05M
-12.72M
-59.01M
Other non operating income
1.47M
1.72M
-351.00K
3.06M
EBT including unusual items
-42.27M
-44.26M
-12.47M
-57.94M
EBT excluding unusual items
-42.92M
-48.10M
-11.96M
-58.53M
Income tax expense
-
2.16M
-7.10M
2.16M
Effective tax rate
-
-4.56%
1.61%
-3.72%
Other operating expenses
-
-
-
-
Net income
-42.27M
-49.48M
-5.37M
-23.49M
Net profit margin
-
-361.39%
-8.96%
-57.48%
Earnings per share
-0.91
-0.92
0.94
-0.43
Interest and investment income
1.36M
1.88M
3.37M
2.55M
Interest expense
-
-4.76M
-2.94M
-5.59M
Net interest expenses
1.36M
-1.45M
-5.28M
-1.67M
Depreciation and amortization charges
-
-
-
-
EBITDA
-45.58M
-45.76M
-12.13M
-23.09M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer